R Street Policy Analysis: 7-OH Bans Risk Unintended Harms While Research Evidence Remains Limited

Why it matters

Policy think tank cautions that rapid 7-OH scheduling without robust evidence could drive users to illicit markets, increase stigma, and hinder clinical research—offering evidence-based critique of prohibition-focused approaches.

The big picture

As of April 19, 2026, at least five states have banned 7-OH and several more are considering federal Schedule I placement. R Street's analysis argues that while bans are well-intentioned, they follow a prohibition-first pattern that historically has created unintended consequences: driving users away from regulated products to illicit markets, increasing stigma that discourages treatment-seeking, and restricting research that could reveal benefits or guide safer use. The institute advocates for regulation aligned with evidence rather than blanket prohibition.

Key findings

• ['At least 5 states have now banned 7-OH as of April 2026; Congress considering Schedule I placement', '7-OH is 5-50 times more potent than mitragynine but occurs naturally in trace amounts (0.1% or less)', 'Both mitragynine and 7-OH are partial mu-receptor agonists with ceiling effect on respiratory depression (unlike full agonists)', 'Kratom used for centuries in SE Asia with few negative effects; recent US 7-OH products are novel concentrated forms', 'Majority of overdose deaths involve polypharmacy (other drugs present); pure 7-OH fatalities rare']

What they say

R Street analysis: 'While these policies are often well-intended, they represent a reactive approach that oversimplifies a complex issue. Across substances, prohibition and even excessive restriction come with dangers of their own, driving people away from regulated options to illicit markets and unregulated products.'

Bottom line

**Policy experts warn that rapid 7-OH bans without evidence-based regulation could mirror past prohibition failures by driving users to illicit markets and hindering research.**